Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18592271 | 0.89 | ABL1 (0.36) | HRH3ABL1ACACBKDM4EALDH1A1 | |
| SCHEMBL20132881 | 0.88 | ABL1 (0.40) | HRH3ABL1ACACBKDM4EALDH1A1 | |
| SCHEMBL24654222 | 0.87 | ABL1 (0.35) | HRH3ABL1ACACBKDM4EALDH1A1 | |
| SCHEMBL20046551 | 0.82 | ABL1 (0.35) | HRH3ABL1ACACBKDM4EALDH1A1 | |
| SCHEMBL21026078 | 0.80 | ABL1 (0.35) | ABL1ACACBNR3C1ACACA | |
| SCHEMBL20133266 | 0.79 | ACACB (0.36) | ABL1ACACBACACA | |
| SCHEMBL20330345 | 0.78 | ABL1 (0.37) | ABL1ACACBKDM4EALDH1A1TDP1 | |
| SCHEMBL20234213 | 0.77 | ABL1 (0.41) | ABL1ACACBKDM4EALDH1A1TDP1 | |
| SCHEMBL18612223 | 0.74 | MTNR1A (0.40) | ABL1ACACBKDM4EALDH1A1ACACA | |
| SCHEMBL24856127 | 0.73 | ABL1 (0.38) | ABL1ACACBKDM4ETDP1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3537/4885ABL1 2227/4885ACACB 1444/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HRH3 3537/4885ABL1 2227/4885ACACB 1444/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | HRH3 3844/4885ABL1 1689/4885ACACB 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.